tetano
Editor, Senior Moderator
J Infect Chemother
. 2021 Nov 18;S1341-321X(21)00321-4.
doi: 10.1016/j.jiac.2021.11.010. Online ahead of print.
Post-COVID-19 interstitial lung disease presenting with profound hypoxemia: Report of three cases demonstrating a good response to high-dose corticosteroid therapy
Kiyoshi Uemasu[SUP] 1 [/SUP], Yuto Yasuda[SUP] 2 [/SUP], Yutaka Hirayama[SUP] 2 [/SUP], Soichi Arasawa[SUP] 3 [/SUP], Daisuke Iwashima[SUP] 2 [/SUP], Ken-Ichi Takahashi[SUP] 2 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which leads to critical pneumonia, although the clinical courses vary. In some cases, COVID-19 pneumonia causes secondary pulmonary fibrosis, which can retain radiological changes and prolong respiratory symptoms. Interstitial lung disease (ILD) secondary to COVID-19 is thought to be caused by multiple pathologies, such as excessive cytokines and abnormal repair processes elaborated by lung cells (epithelium, mesenchyme, and alveolar macrophages) after lung injury rather than viral invasion itself. Immunosuppression therapy may improve chronic respiratory symptoms and radiological changes in post-COVID-19 ILD, although the treatment is not yet established. Herein, we report three patients with post-COVID-19 ILD who presented with profound hypoxemia that had a good response to high-dose corticosteroid therapy. Further and larger studies are needed to establish post-COVID-19 ILD.
Keywords: COVID-19; Corticosteroid therapy; Interstitial lung disease; Post-COVID-19; SARS-CoV-2.
. 2021 Nov 18;S1341-321X(21)00321-4.
doi: 10.1016/j.jiac.2021.11.010. Online ahead of print.
Post-COVID-19 interstitial lung disease presenting with profound hypoxemia: Report of three cases demonstrating a good response to high-dose corticosteroid therapy
Kiyoshi Uemasu[SUP] 1 [/SUP], Yuto Yasuda[SUP] 2 [/SUP], Yutaka Hirayama[SUP] 2 [/SUP], Soichi Arasawa[SUP] 3 [/SUP], Daisuke Iwashima[SUP] 2 [/SUP], Ken-Ichi Takahashi[SUP] 2 [/SUP]
Affiliations
- PMID: 34810106
- DOI: 10.1016/j.jiac.2021.11.010
Abstract
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which leads to critical pneumonia, although the clinical courses vary. In some cases, COVID-19 pneumonia causes secondary pulmonary fibrosis, which can retain radiological changes and prolong respiratory symptoms. Interstitial lung disease (ILD) secondary to COVID-19 is thought to be caused by multiple pathologies, such as excessive cytokines and abnormal repair processes elaborated by lung cells (epithelium, mesenchyme, and alveolar macrophages) after lung injury rather than viral invasion itself. Immunosuppression therapy may improve chronic respiratory symptoms and radiological changes in post-COVID-19 ILD, although the treatment is not yet established. Herein, we report three patients with post-COVID-19 ILD who presented with profound hypoxemia that had a good response to high-dose corticosteroid therapy. Further and larger studies are needed to establish post-COVID-19 ILD.
Keywords: COVID-19; Corticosteroid therapy; Interstitial lung disease; Post-COVID-19; SARS-CoV-2.